TG Therapeutics, Inc.

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases, including malignancies and autoimmune disorders, in the United States and internationally. Its lead product, BRIUMVI (ublituximab-xiiy), is an anti-CD20 monoclonal antibody approved for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), encompassing clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The company advances a pipeline featuring TG-1701, an orally available covalent Bruton's tyrosine kinase (BTK) inhibitor selective for BTK; TG-1801, a bispecific CD47 and CD19 antibody; and azer-cel, an allogeneic CD19 CAR T therapy, all targeting B-cell disorders and currently in early clinical stages. TG Therapeutics, Inc. generates revenue primarily from BRIUMVI net product sales in the U.S., with additional contributions from international partners. Founded in 1993 and headquartered in Morrisville, North Carolina, it plays a key role in addressing unmet needs in neurology and oncology through targeted immunotherapies.